Beaurain et al., 2019 - Google Patents
Innovative molecular imaging for clinical research, therapeutic stratification, and nosography in neuroscienceBeaurain et al., 2019
View HTML- Document ID
- 16434651385069045833
- Author
- Beaurain M
- Salabert A
- Ribeiro M
- Arlicot N
- Damier P
- Le Jeune F
- Demonet J
- Payoux P
- Publication year
- Publication venue
- Frontiers in medicine
External Links
Snippet
Over the past few decades, several radiotracers have been developed for neuroimaging applications, especially in PET. Because of their low steric hindrance, PET radionuclides can be used to label molecules that are small enough to cross the blood brain barrier …
- 238000003384 imaging method 0 title abstract description 181
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Beaurain et al. | Innovative molecular imaging for clinical research, therapeutic stratification, and nosography in neuroscience | |
Sabri et al. | Acetylcholine receptors in dementia and mild cognitive impairment | |
Villemagne et al. | In vivo tau imaging: obstacles and progress | |
Maeda et al. | In vivo positron emission tomographic imaging of glial responses to amyloid-β and tau pathologies in mouse models of Alzheimer's disease and related disorders | |
Vallabhajosula | Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid | |
TWI432214B (en) | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents | |
Lazarova et al. | Synthesis and evaluation of [N-methyl-11C] N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function | |
JP2004506723A (en) | Thioflavin derivatives for use in prenatal diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposits | |
Teng et al. | [F-18] FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment | |
Sundaram et al. | Fluselenamyl: a novel benzoselenazole derivative for PET detection of amyloid plaques (Aβ) in Alzheimer’s disease | |
Wanek et al. | Factors governing P-glycoprotein-mediated drug–drug interactions at the blood–brain barrier measured with positron emission tomography | |
Svedberg et al. | Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease | |
JP2023525081A (en) | Novel compounds for diagnostics | |
Kaide et al. | Identification and evaluation of bisquinoline scaffold as a new candidate for α-synuclein-PET imaging | |
Declercq et al. | Drug development in Alzheimer’s disease: the contribution of PET and SPECT | |
Tu et al. | Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter | |
Nwabufo et al. | Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease | |
Giboureau et al. | PET radioligands for the vesicular acetylcholine transporter (VAChT) | |
Ono et al. | SPECT Imaging Agents for Detecting Cerebral β‐Amyloid Plaques | |
Boswijk et al. | Potential of α7 nicotinic acetylcholine receptor PET imaging in atherosclerosis | |
Agha et al. | In vitro and in vivo sigma 1 receptor imaging studies in different disease states | |
Kim et al. | Screening of σ2 receptor ligands and in vivo evaluation of 11C-labeled 6, 7-Dimethoxy-2-[4-(4-methoxyphenyl) butan-2-yl]-1, 2, 3, 4-tetrahydroisoquinoline for potential use as a σ2 receptor brain PET tracer | |
Zeng et al. | Current progress in the development of probes for targeting α-synuclein aggregates | |
Zhang et al. | Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography | |
Kong et al. | Relationship Between Reactive Astrocytes, by [18F] SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease |